|
- Biologicals - World Health Organization (WHO)
The beneficial impact of biologicals is as diverse as the types of products themselves: Vaccines are one of the most powerful and cost-effective ways to reduce the global burden of disease and are estimated to save 2–3 million lives every year
- Biosimilars: expanding access to essential biologic therapies
Biologics are complex medicines derived from living organisms Their complex manufacturing processes have traditionally limited their availability, primarily serving high-income countries In recent years, biopharmaceutical manufacturing capacity has grown faster in middle-income countries, increasing the potential for broader access
- Call for applications closed - 2025 Introductory course for biologics . . .
Proposed dates for the 2025 Introductory Course for Biologics Development and Manufacturing are: Monday, June 16, 2025 – Friday, June 27, 2025 (2 Weeks) Course Objectives After completing the course, participants will have basic and primary knowledge about various areas that are related to biologics manufacturing
- Biologicals - World Health Organization (WHO)
Biologicals are a class of medicines made from living cells taken from plants, animals or bacteria These cells are use in creating many types of health care products, including vaccines This group of medicines also includes products derived from human blood and plasma for the treatment of many life-threatening diseases and for surgical procedures
- Guidelines for Biologicals - World Health Organization (WHO)
Recommendations to assure the quality, safety and efficacy of BCG vaccines, Annex 3, TRS No 979
- WHO good manufacturing practices for biological products
93 Annex 2 WHO good manufacturing practices for biological products Replacement of Annex 1 of WHO Technical Report Series, No 822
- Introductory Course for Biologics Development and Manufacturing . . .
Low- and Middle-Income Countries (LMICs) face significant inequity in terms of access to vaccines and other biologics and are making efforts to establish biological manufacturing in their regions Establishing such manufacturing capacity, through bilateral technology transfer or through local R D efforts is often hindered by the lack of a trained workforce in biomanufacturing To address this
- Introductory course for biologics development and manufacturing
In-person (by application)Date: 16-27 June 2025 (two-week course) Languages: English Low- and middle-income countries (LMICs) face significant inequity in terms of access to vaccines and other biologics and are making efforts to establish biological manufacturing in their regions However, bilateral technology transfer and local research and development efforts are often hindered by the lack
|
|
|